Psychedelics and the Essential Importance of Context
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Microdosing Psychedelics: Results from the Global Drug Survey 2019
Microdosing Psychedelics: Results from the Global Drug Survey 2019 Petranker, R.1,2, Anderson, T.2,3, Maier, L. J.4,5, Barratt, M. J.6,7, Ferris, J. A.8, & Winstock, A. R.9,10 1 Clinical Psychology, York University, Toronto, ON, Canada 2 Psychedelic Studies Research Program, University of Toronto Mississauga, Mississauga, ON, Canada 3 Department of Psychology, University of Toronto, Toronto, ON, Canada. 4 Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, CA, United States 5 Early Postdoc Mobility Grantee, Swiss National Science Foundation, Bern, Switzerland 6 Social and Global Studies Centre, RMIT University, Australia 7 National Drug and Alcohol Research Centre, UNSW Sydney, Australia 8 Centre for Health Services Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia 9 University College London, Gower St, Bloomsbury, London, UK 10 Global Drug Survey Ltd, London, UK *Corresponding Author Rotem Petranker Toronto, ON, Canada Email: [email protected] Abstract Microdosing psychedelics – the practice of taking small, sub-hallucinogenic amounts of substances like psilocybin-containing mushrooms or LSD – is becoming increasingly popular. Despite its surging popularity, little is known about the effects of this practice. This research had two aims. First, we attempted to replicate previous findings in the literature regarding the subjective benefits and challenges involved in microdosing. Second, we wanted to examine whether people who microdose test their substances for purity before consumption, and whether approach-intention to microdosing was predictive of more reported benefits. 7,313 people who reported microdosing, from a variety of countries, ages, and other demographics participated in our survey. -
From Sacred Plants to Psychotherapy
From Sacred Plants to Psychotherapy: The History and Re-Emergence of Psychedelics in Medicine By Dr. Ben Sessa ‘The rejection of any source of evidence is always treason to that ultimate rationalism which urges forward science and philosophy alike’ - Alfred North Whitehead Introduction: What exactly is it that fascinates people about the psychedelic drugs? And how can we best define them? 1. Most psychiatrists will define psychedelics as those drugs that cause an acute confusional state. They bring about profound alterations in consciousness and may induce perceptual distortions as part of an organic psychosis. 2. Another definition for these substances may come from the cross-cultural dimension. In this context psychedelic drugs may be recognised as ceremonial religious tools, used by some non-Western cultures in order to communicate with the spiritual world. 3. For many lay people the psychedelic drugs are little more than illegal and dangerous drugs of abuse – addictive compounds, not to be distinguished from cocaine and heroin, which are only understood to be destructive - the cause of an individual, if not society’s, destruction. 4. But two final definitions for psychedelic drugs – and those that I would like the reader to have considered by the end of this article – is that the class of drugs defined as psychedelic, can be: a) Useful and safe medical treatments. Tools that as adjuncts to psychotherapy can be used to alleviate the symptoms and course of many mental illnesses, and 1 b) Vital research tools with which to better our understanding of the brain and the nature of consciousness. Classifying psychedelic drugs: 1,2 The drugs that are often described as the ‘classical’ psychedelics include LSD-25 (Lysergic Diethylamide), Mescaline (3,4,5- trimethoxyphenylathylamine), Psilocybin (4-hydroxy-N,N-dimethyltryptamine) and DMT (dimethyltryptamine). -
Ritualized Peyote Use Can Facilitate Mental Health, Social Solidarity
Ritualized Peyote Use Can Facilitate Mental Health, Social Solidarity, and Cultural Survival: A Case Study of the Religious and Mystical Experiences in the Wixárika People of the Sierra Madre Occidental The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Luce, Nathan William. 2020. Ritualized Peyote Use Can Facilitate Mental Health, Social Solidarity, and Cultural Survival: A Case Study of the Religious and Mystical Experiences in the Wixárika People of the Sierra Madre Occidental. Master's thesis, Harvard Extension School. Citable link https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37365056 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Ritualized Peyote Use Can Facilitate Mental Health, Social Solidarity, and Cultural Survival: A Case Study of the Religious and Mystical Experiences in the Wixárika People of the Sierra Madre Occidental Nathan William Luce A Thesis in the Field of Religion for the Degree of Master of Liberal Arts in Extension Studies Harvard University May 2020 Copyright 2020 Nathan William Luce Abstract This paper examines how the Wixárika, or Huichol, as they are more commonly known to the outside world, have successfully engaged in a decade-long struggle to save their ceremonial homeland of Wirikuta. They have fended off a Canadian silver mining company’s attempts to dig mines in the habitat of their most important sacrament, peyote, using a remarkable combination of traditional and modern resistance techniques. -
Psilocybin Mushrooms Fact Sheet
Psilocybin Mushrooms Fact Sheet January 2017 What are psilocybin, or “magic,” mushrooms? For the next two decades thousands of doses of psilocybin were administered in clinical experiments. Psilocybin is the main ingredient found in several types Psychiatrists, scientists and mental health of psychoactive mushrooms, making it perhaps the professionals considered psychedelics like psilocybin i best-known naturally-occurring psychedelic drug. to be promising treatments as an aid to therapy for a Although psilocybin is considered active at doses broad range of psychiatric diagnoses, including around 3-4 mg, a common dose used in clinical alcoholism, schizophrenia, autism spectrum disorders, ii,iii,iv research settings ranges from 14-30 mg. Its obsessive-compulsive disorder, and depression.xiii effects on the brain are attributed to its active Many more people were also introduced to psilocybin metabolite, psilocin. Psilocybin is most commonly mushrooms and other psychedelics as part of various found in wild or homegrown mushrooms and sold religious or spiritual practices, for mental and either fresh or dried. The most popular species of emotional exploration, or to enhance wellness and psilocybin mushrooms is Psilocybe cubensis, which is creativity.xiv usually taken orally either by eating dried caps and stems or steeped in hot water and drunk as a tea, with Despite this long history and ongoing research into its v a common dose around 1-2.5 grams. therapeutic and medical benefits,xv since 1970 psilocybin and psilocin have been listed in Schedule I of the Controlled Substances Act, the most heavily Scientists and mental health professionals criminalized category for drugs considered to have a consider psychedelics like psilocybin to be “high potential for abuse” and no currently accepted promising treatments as an aid to therapy for a medical use – though when it comes to psilocybin broad range of psychiatric diagnoses. -
Community and Practice in Two Generations of Online Illicit Drugs Discussions
Community and practice in two generations of online illicit drugs discussions A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Humanities. 2020 P. O. Enghoff School of Social Sciences, Department of Criminology and Criminal Justice Table of Contents Abstract .................................................................................................................. 5 Acknowledgements .............................................................................................. 8 Other acknowledgements .................................................................................... 9 The author .............................................................................................................. 9 Chapter 1. Introduction ..................................................................................... 10 1.1 Background ........................................................................................... 11 1.2 Summary of thesis contents ................................................................ 19 1.2.1 Literature review .......................................................................... 20 1.2.2 Research design ............................................................................. 24 1.2.3 Research papers ............................................................................ 28 1.2.4 Discussion ...................................................................................... 31 Chapter 2. Literature review ............................................................................ -
Neural and Subjective Effects of Inhaled DMT in Natural Settings
bioRxiv preprint doi: https://doi.org/10.1101/2020.08.19.258145; this version posted August 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Neural and subjective effects of inhaled DMT in natural settings Carla Pallavicini1,2 *, Federico Cavanna1,2, Federico Zamberlan1, Laura Alethia de la Fuente1, Mauricio Arias3, Celeste Romero4, Robin Carhart-Harris5, Christopher Timmermann5, Enzo Tagliazucchi1 * 1Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA – CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina 2Fundación para la lucha contra las enfermedades neurológicas de la infancia (FLENI), Montañeses 2325, C1428 CABA, Buenos Aires, Argentina 3Hospital General de Agudos Donación Francisco Santojanni, Pilar 950, C1408INH CABA, Buenos Aires, Argentina 4Centro de Estudios de la Cultura Cannábica (CECCa), Humahuaca 3947, C1192ACA CABA, Buenos Aires, Argentina 5Centre for Psychedelic Research, Department of Medicine, Imperial College London, Kensington, London SW7 2DD, United Kingdom *Corresponding authors: [email protected] , [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.19.258145; this version posted August 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract N,N-Dimethyltryptamine (DMT) is a short acting psychedelic tryptamine found naturally in many plants and animals. -
CLINICAL STUDY PROTOCOL Psilocybin-Assisted Psychotherapy
CLINICAL STUDY PROTOCOL Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma. Version: Final IND: [79,321] SPONSOR Multidisciplinary Association for Psychedelic PRINCIPAL INVESTIGATOR Sameet Kumar Ph.D. MEDICAL MONITOR Michael C. Mithoefer MD. STUDY PERSONNEL XXXXXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXXXXXX STUDY MONITOR [CRA] Valerie Mojeiko IRB Study Site IRB Sponsor Signatory Rick Doblin Ph.D. Study Period 2008 For trial related emergencies please contact: Dr. Michael Mithoefer MAPS: S Kumar PI Clinical Study Protocol PCA1 Final December 1, 2007 Confidential Page 2 of 83 Table of Contents Introduction......................................................................................................................... 4 Background..................................................................................................................... 4 Disease History and Related Research ........................................................................... 5 Rationale ......................................................................................................................... 7 Summary......................................................................................................................... 7 Ethics................................................................................................................................... 8 Informed Consent of Subject .......................................................................................... 9 Recruitment and Screening............................................................................................ -
The Psychedelic Experience: the Importance of ‘Set’ and ‘Setting’
The Psychedelic Experience: The Importance of ‘Set’ and ‘Setting’ Matthew Nour & Jacob Krzanowski Matthew Nour, CT1 in Psychiatry, South London and Maudsley NHS Foundation Trust; Jacob Krzanowski, CT1 in Psychiatry, South London and Maudsley NHS Foundation Trust. Email: [email protected] *Both authors contributed equally to this work We welcome the renewed interest in the therapeutic potential of psychedelic compounds. In their recent editorial, Sessa and Johnson1 echo the fervent research climate surrounding psychedelics spanning the 1950s and 60s. They suggest that psychedelics may cause prolonged changes in subjects’ personalities and attitudes following mystical-spiritual experiences. This unique and exciting potential mechanism of action certainly warrants the current renaissance in psychedelic research, and has important implications for study design and subject selection. As we move towards re-exploring the clinical applications of psychedelics, however, we must appreciate that the phenomenology of the psychedelic experience is likely to depend not only on a drug’s pharmacodynamic properties, but also on the makeup of the subject (‘set’) and the environmental context (‘setting’) in which the drug is administered. Recent work suggests that the potential importance of ‘set’ in the psychedelic experience should not be overlooked. Hallucinogenic compounds act via the serotonergic 5-HT2A receptor to effect experience and behaviour. Genetic and neuroimaging evidence suggests that inter-subject differences in serotonergic neurotransmission -
BC2019-Printproginccovers-High.Pdf
CONTENTS Welcome with Acknowledgements 1 Talk Abstracts (Alphabetically by Presenter) 3 Programme (Friday) 32–36 Programme (Saturday) 37–41 Programme (Sunday) 42–46 Installations 47–52 Film Festival 53–59 Entertainment 67–68 Workshops 69–77 Visionary Art 78 Invited Speaker & Committee Biographies 79–91 University Map 93 Area Map 94 King William Court – Ground Floor Map 95 King William Court – Third Floor Map 96 Dreadnought Building Map (Telesterion, Underworld, Etc.) 97 The Team 99 Safer Spaces Policy 101 General Information 107 BREAK TIMES - ALL DAYS 11:00 – 11:30 Break 13:00 – 14:30 Lunch 16:30 – 17:00 Break WELCOME & ACKNOWLEDGEMENTS WELCOME & ACKNOWLEDGEMENTS for curating the visionary art exhibition, you bring that extra special element to BC. Ashleigh Murphy-Beiner & Ali Beiner for your hard work, in your already busy lives, as our sponsorship team, which gives us more financial freedom to put on such a unique event. Paul Callahan for curating the Psychedelic Cinema, a fantastic line up this year, and thanks to Sam Oliver for stepping in last minute to help with this, great work! Andy Millns for stepping up in programming our installations, thank you! Darren Springer for your contribution to the academic programme, your perspective always brings new light. Andy Roberts for your help with merchandising, and your enlightening presence. Julian Vayne, another enlightening and uplifting presence, thank you for your contribution! To Rob Dickins for producing the 8 circuit booklet for the welcome packs, and organising the book stall, your expertise is always valuable. To Maria Papaspyrou for bringing the sacred feminine and TRIPPth. -
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209 -
Ecstasy and Club Drugs
Ecstasy and Club Drugs The term “club drug” refers to drugs being used by youth and young adults at all-night dance parties such as “raves” or “trances,” dance clubs and bars. MDMA (Ecstasy), GHB, Rohypnol, Ketamine, Methamphetamine, and LSD are among the drugs referred to as “club drugs.” “Raves” are a form of dance and recreation that is held in a clandestine location with fast-paced, high-volume music, a variety of high-tech entertainment and usually the use of “club drugs.” Ecstasy Ecstasy or MDMA (methylenedioxymethamphetamine) is a stimulant that combines the properties of methamphetamine or “speed” with mind-altering or hallucinogenic properties. It is considered to be the most commonly used club (or “designer” drug). Ecstasy is an illegal drug (it was declared illegal by the federal government in 1985) 90% of which is manufactured in the Netherlands and Belgium. In its most common form, Ecstasy is a small tablet that is impressed with any one of a number of logos intended to attract young people. It can also be in capsule or powder form and can be injected. Among the street names for Ecstasy are Adam, X-TC, Clarity, Essence, Stacy, Lover’s Speed, Eve, etc. The Ecstasy high can last from 6 to 24 hours, with the average “trip” lasting only about 3-4 hours. Users of Ecstasy report that it causes mood changed and loosens their inhibitions; they become more outgoing, empathetic and affectionate. For this reason, Ecstasy has been called the “hug drug.” It also suppresses the need to eat, drink or sleep, enabling users to endure parties that can last for two or three days. -
2021 Information Packet
The Center for Psychedelic Therapies and Research The 2021 Certificate Program in Psychedelic-Assisted Therapies and Research Quick FAQs about the 2021 Certificate Program • The 2021 classes run from April 2021 to December 2021. • Eligibility criteria are strictly limited to specific licensed medical and mental health professionals, counseling attorneys, ordained clergy and commissioned chaplains. • The application period for 2021 is open from October 15, 2020 to November 30, 2020. • Interested in learning more details? Read more here. Dr. Janis Phelps, Director Center for Psychedelic Therapies and Research California Institute of Integral Studies 1453 Mission Street San Francisco, CA. Table of Contents About The Program 2 Exciting Updates For The 2021 Class 2 Philosophy And Goals Of The Certificate 3 Institutional Partners And Acknowledgements 3 Planned 2021 Certificate Teachers 4 Format Of The Certificate Program 5 Schedule Boston And San Francisco 2021 Classes 6 What Can I Do With This Certificate In Psychedelic-Assisted Therapies And Research? 8 What Are The Benefits Of Attending The Certificate Program In Psychedelic-Assisted Therapies And Research? 8 Application Dates For The 2021 Class 9 2021 Eligibility Criteria For The Certificate 10 2021 Application Materials 12 Scholarships And Need-Based Aid 13 2021 Payment And Withdrawal Policies 13 Curriculum Of The Certificate 16 Online Information Sessions On The 2021 Certificate Program 17 Contact Information 17 About the Program This Certificate Program is housed in the CIIS Center for Psychedelic Therapies and Research. The Center also provides diverse public education about psychedelic research and the use of psychedelics in psychotherapy from the past decades, as well as teaching on topics such as creativity enhancement, consciousness studies, comparative mysticism, well-being enrichment, and harm reduction.